Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025
Alpha Cognition (NASDAQ: ACOG) has successfully launched its product ZUNVEYL(R) (benzgalantamine) in the U.S. long-term care (LTC) market on March 17, 2025. The launch has shown positive early results with strong clinician and patient feedback, successful patient outcomes, and robust ordering momentum. The company secured Medicare reimbursement post-launch, enhancing patient access in LTC settings. Additionally, ACOG obtained a new composition of matter patent for the tablet formulation of benzgalantamine in the U.S.
Financial highlights include ZUNVEYL net product revenues of $0.35M and licensing revenue of $2.6M. Management confirmed that all launch objectives remain on track and within budget, with commercial execution proceeding according to plan.
Alpha Cognition (NASDAQ: ACOG) ha lanciato con successo il suo prodotto ZUNVEYL(R) (benzgalantamina) nel mercato statunitense dell'assistenza a lungo termine (LTC) il 17 marzo 2025. Il lancio ha mostrato risultati iniziali positivi con un riscontro favorevole da parte di clinici e pazienti, esiti terapeutici efficaci e un solido slancio negli ordini. L'azienda ha ottenuto il rimborso Medicare dopo il lancio, migliorando l'accesso dei pazienti nelle strutture LTC. Inoltre, ACOG ha acquisito un nuovo brevetto per la composizione della formulazione in compresse di benzgalantamina negli Stati Uniti.
I dati finanziari evidenziano ricavi netti da prodotto ZUNVEYL pari a 0,35 milioni di dollari e ricavi da licenze per 2,6 milioni di dollari. La direzione ha confermato che tutti gli obiettivi del lancio sono rispettati e rientrano nel budget, con l'esecuzione commerciale che procede secondo i piani.
Alpha Cognition (NASDAQ: ACOG) ha lanzado con éxito su producto ZUNVEYL(R) (benzgalantamina) en el mercado estadounidense de cuidados a largo plazo (LTC) el 17 de marzo de 2025. El lanzamiento ha mostrado resultados iniciales positivos con una fuerte retroalimentación de médicos y pacientes, resultados exitosos para los pacientes y un sólido impulso en los pedidos. La empresa aseguró el reembolso de Medicare tras el lanzamiento, mejorando el acceso de los pacientes en entornos LTC. Además, ACOG obtuvo una nueva patente de composición para la formulación en tabletas de benzgalantamina en Estados Unidos.
Los aspectos financieros incluyen ingresos netos por producto ZUNVEYL de 0,35 millones de dólares e ingresos por licencias de 2,6 millones de dólares. La dirección confirmó que todos los objetivos del lanzamiento están en camino y dentro del presupuesto, con la ejecución comercial avanzando según lo planeado.
Alpha Cognition (NASDAQ: ACOG)는 2025년 3월 17일 미국 장기 요양(LTC) 시장에 자사 제품 ZUNVEYL(R) (벤즈갈란타민)을 성공적으로 출시했습니다. 이번 출시는 임상 의사와 환자들의 긍정적인 피드백, 성공적인 환자 결과, 그리고 견고한 주문 증가세를 보이며 초기 좋은 성과를 나타냈습니다. 회사는 출시 후 메디케어 상환을 확보하여 LTC 환경에서 환자 접근성을 향상시켰습니다. 또한 ACOG는 미국에서 벤즈갈란타민 정제 제형에 대한 새로운 조성물 특허를 취득했습니다.
재무 하이라이트로는 ZUNVEYL 순제품 매출 35만 달러 및 라이선스 수익 260만 달러가 포함됩니다. 경영진은 모든 출시 목표가 계획대로 예산 내에서 순조롭게 진행되고 있음을 확인했습니다.
Alpha Cognition (NASDAQ : ACOG) a lancé avec succès son produit ZUNVEYL(R) (benzgalantamine) sur le marché américain des soins de longue durée (LTC) le 17 mars 2025. Ce lancement a donné des résultats positifs précoces avec un retour favorable des cliniciens et des patients, des résultats patients réussis et un fort dynamisme des commandes. L'entreprise a obtenu le remboursement Medicare après le lancement, améliorant l'accès des patients dans les établissements LTC. De plus, ACOG a obtenu un nouveau brevet de composition pour la formulation en comprimés de benzgalantamine aux États-Unis.
Les points financiers clés incluent des revenus nets produits ZUNVEYL de 0,35 M$ et des revenus de licences de 2,6 M$. La direction a confirmé que tous les objectifs du lancement restent sur la bonne voie et dans le budget, avec une exécution commerciale conforme au plan.
Alpha Cognition (NASDAQ: ACOG) hat sein Produkt ZUNVEYL(R) (Benzgalantamin) am 17. März 2025 erfolgreich auf dem US-amerikanischen Markt für Langzeitpflege (LTC) eingeführt. Der Produktstart zeigte positive erste Ergebnisse mit starkem Feedback von Klinikern und Patienten, erfolgreichen Behandlungsergebnissen und robustem Bestellwachstum. Das Unternehmen sicherte sich nach dem Start die Medicare-Erstattung, was den Zugang der Patienten in LTC-Einrichtungen verbessert. Zudem erhielt ACOG ein neues Patent für die Zusammensetzung der Tablettenformulierung von Benzgalantamin in den USA.
Finanzielle Highlights umfassen ZUNVEYL Nettoprodukterlöse von 0,35 Mio. USD und Lizenzumsätze von 2,6 Mio. USD. Das Management bestätigte, dass alle Ziele des Produktstarts im Zeitplan und im Budget liegen und die kommerzielle Umsetzung planmäßig verläuft.
- Successful launch of ZUNVEYL in U.S. long-term care market
- Secured Medicare reimbursement, improving market access
- Obtained new composition of matter patent for tablet formulation
- Generated $0.35M in product revenue and $2.6M in licensing revenue
- Strong initial ordering momentum and positive clinical feedback
- Initial product revenue of $0.35M indicates early-stage commercialization with limited market penetration
Dallas, Texas--(Newsfile Corp. - May 19, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition began 2025 by launching ZUNVEYL(R) (benzgalantamine) to the U.S. long-term care (LTC) market on March 17, 2025, delivering on its commercialization timeline and budget. Early clinician and patient feedback has been positive, citing successful initial patient outcomes and strong ordering momentum, with rapid product replenishment by wholesalers. The field team reported broad engagement across high-priority LTC accounts nationwide. Importantly, Medicare reimbursement was secured soon after launch, significantly improving access for patients in LTC settings. Management reiterated that all launch objectives remain on track and within budget, with commercial execution progressing as planned.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
Officially launched ZUNVEYL to US market in March, 2025.
The Company secured a new composition of matter patent in the U.S., covering the tablet formulation of benzgalantamine.
ZUNVEYL net product revenues of
$0.35M ; with licensing revenue of$2.6M .
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252571
FAQ
What is the revenue generated by ACOG's ZUNVEYL in Q1 2025?
When did Alpha Cognition launch ZUNVEYL in the US market?
What recent patent did Alpha Cognition (ACOG) secure for ZUNVEYL?
Has ZUNVEYL received Medicare reimbursement approval?
How has the market responded to ZUNVEYL's launch by Alpha Cognition?
